https://www.selleckchem.com/products/icrt3.html
7%), and pertuzumab (62.9%). Median administration time of trastuzumab at the switch was 13 administrations (range 2-14. Premedication was administered to 20.7% patients. One patient (0.7%) experienced grade 3 IRR. The frequency of diarrhea in the reference trastuzumab group and the CT-P6 group was 7.1 and 6.4%, respectively, and that of skin toxicity was 6.4 and 5.0%, respectively, without differences. In conclusion, we first demonstrated that an initial CT-P6 administration for 30 min during the switch from reference trastuzumab in ma
Like
Comment
Share
